Latest round: Post-IPO. Tom Graney is the Chief Executive Officer of Oxurion, a biotech drug development company specializing in therapies for retinal.
Tom Graney is the Chief Executive Officer of Oxurion, a biotech drug development company specializing in therapies for retinal disorders, with a current focus on diabetic eye diseases. He was appointed to this role on May 17, 2021. Oxurion is a public company based in Heverlee, Belgium.
Full founder directory · Investor directory · Company funding database · Fundraising library